Israel - Ibrani - Ministry of Health

j-c health care ltd - ibrutinib - קפסולות - ibrutinib 140 mg

Israel - Ibrani - Ministry of Health

j-c health care ltd - ibrutinib - קפסולות - ibrutinib 140 mg

Israel - Ibrani - Ministry of Health

j-c health care ltd - ibrutinib - טבליות מצופות פילם - ibrutinib 140 mg - ibrutinib

Israel - Ibrani - Ministry of Health

j-c health care ltd - ibrutinib - טבליות מצופות פילם - ibrutinib 280 mg - ibrutinib

Israel - Ibrani - Ministry of Health

j-c health care ltd - ibrutinib - טבליות מצופות פילם - ibrutinib 420 mg - ibrutinib

Israel - Ibrani - Ministry of Health

j-c health care ltd - ibrutinib - טבליות מצופות פילם - ibrutinib 560 mg - ibrutinib

Israel - Ibrani - Ministry of Health

teva pharmaceutical industries ltd, israel - boric acid; diphenhydramine hydrochloride; naphazoline hydrochloride - טיפות עיניים - boric acid 2.2 %; diphenhydramine hydrochloride 0.1 %; naphazoline hydrochloride 0.025 % - sympathomimetics used as decongestants - allergic conditions of the conjunctiva, conjunctivitis vernalis, conjunctivitis phylactaenulosa, kerato-conjunctivitis, episcleritis.

Israel - Ibrani - Ministry of Health

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 30 mu/ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).

Israel - Ibrani - Ministry of Health

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 48 mu / 0.5 ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).

Israel - Ibrani - Ministry of Health

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 30 mu / 0.5 ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).